Pathfinder Arrives in MapleStory M’s December Update
17.12.2021 01:03:00 EET | Business Wire | Press release
MapleStory M, Nexon’s popular free-to-play mobile MMORPG, has officially launched its latest update, bringing the long-awaited Pathfinder class to the game alongside a flurry of winter season events and activities for Maplers to tackle. The Pathfinder update has also increased the max level to 250, and brings new daily and weekly missions, achievements, and a new mini-dungeon to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006140/en/
Pathfinder Arrives in MapleStory M’s December Update (Graphic: Business Wire)
As of today, the sharpshooting Explorer who wields an ancient bow, Pathfinder, is available as a new playable class. Maplers who pre-registered their Pathfinder were eligible for items such as Auto Battle Charge Tickets and EXP tickets, while all players can take part in Mega Burning and On-Time/Growth Support events to help level-up a new Pathfinder quickly. As a bonus after today’s maintenance, both MapleStory M and MapleStory will be running the Pathfinder Link Event through January 19, 2022, whereby, after reaching level, 70, 120, and 140 on MapleStory M with the Pathfinder, Maplers can garner rewards in both games, including a Pathfinder outfit gift box, Ancient Relic, and more.
The Black Mage's fourth commander, Arkarium, formerly a servant under Rhinne, Maple World's Transcendent of Time, makes his debut in MapleStory M. Maplers will be able to craft all-new boss accessory Dominator Pendant using the materials acquired when defeating Arkarium.
A new map in the Arcane River has also been added, the Dreaming City Lachelein, bringing with it new quests, monsters, area items to discover, and a new Arcane force field. Mini-dungeons have also received a quality of life improvement with this update so that Maplers can auto-play multiple times by using tickets and mesos.
In addition to the events celebrating the arrival of Pathfinder, players can look forward to numerous winter seasonal events occurring throughout December and into the new year:
- I&B Burning Challenge Mission Event - From December 15, 2021 through January 19, 2022, this event returns, granting not only Ice Agent or Burning Agent player titles, but also granting daily missions for players to conquer.
- Holiday Mr. Kim’s Gift - From December 22 through December 30, 2021, tapping on Mr. Kim will reward players with special items.
-
Winter Happyville
Events - (Various scheduled times - refer to in-game event banner or see MapleStoryM patch notes for exact times and dates for each event.) Winter Happy Village will play host to multiple winter events throughout December and January :
- Coin Drop Event
- A Well-Behaved Child Needs A Gift!
- A Crying Child Also Needs A Gift!
- Buff Tree Event
- Great Rudolph Escape
- 2022 Countdown Event - From December 23, 2021 through January 6, 2022, players can enter the event map every day and receive EXP for ten minutes. After spending ten minutes on the map, these players will receive a countdown reward and, on January 1, Maplers can earn a special New Year reward!
- Snowflake Snowpark - From January 6 through January 18, 2022, Maplers can earn AB tickets, EXP tickets, and Gold Leaf by clearing different missions and receiving stamps.
- 2022 New Year Wheel - From January 13 through January 27, 2022, players can receive a maximum of 5 wheel tickets per day by hunting. Rewards for participating in the event include AB tickets, Luckyday scroll 5%, cubes, EXP tickets, and more.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006140/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom